Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer

Lookup NU author(s): Dr Sam Tingle, John Moir, Steven White

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2018 Wiley Periodicals, Inc. Background and Objectives: Several serum based-markers and ratios have been investigated for their prognostic value in pancreatic ductal adenocarcinoma (PDAC). This cohort study aimed to combine these into a novel prognostic scoring system. Methods: A retrospective cohort study was performed on 145 patients with unresectable histologically-confirmed PDAC. Based on the existing literature the following markers were investigated: neutrophil-lymphocyte ratio (NLR), neutrophil-albumin ratio (NAR), platelet-lymphocyte ratio (PLR), fibrinogen, and Ca19-9. These values were dichotomized about their medians for Kaplan-Meier and Cox regression analysis. Results: Univariate Cox regression revealed statistically significant prognostic value for: NLR, NAR, PLR, fibrinogen, and Ca19-9. When combining these using Cox regression analysis adjusting for other prognostic indicators, only NAR (hazard ratios [HR] = 3.174, P = 0.022) and Ca19-9 (HR = 2.697, P = 0.031) were independent predictors of survival. Combining NAR and Ca19-9 we split the cohort into three “NARCA” groups: NARCA0 = NAR ≤ 0.13 and Ca19-9 ≤ 770, NARCA1 = either NAR > 0.13 or Ca19-9 >770, NARCA2 = NAR > 0.13 and Ca19-9 > 770. Median survival was 20.5, 9.7 and 4.1 months in NARCA0, 1, and 2 respectively (P < 0.0005, log-rank test). A separate validation cohort confirmed the prognostic significance of the score (P = 0.048). Conclusions: Combining NAR and Ca19-9 into a prognostic score allows stratification of unresectable PDAC patients into groups with significantly different overall survival.

Publication metadata

Author(s): Tingle SJ, Severs GR, Goodfellow M, Moir JA, White SA

Publication type: Article

Publication status: Published

Journal: Journal of Surgical Oncology

Year: 2018

Volume: 118

Issue: 4

Pages: 680-686

Print publication date: 15/09/2018

Online publication date: 09/09/2018

Acceptance date: 26/07/2018

ISSN (print): 0022-4790

ISSN (electronic): 1096-9098

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1002/jso.25209

DOI: 10.1002/jso.25209

Altmetrics

Altmetrics provided by Altmetric

Share